...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: One More Promissory Note-Aug 9/24

I doubt if we will see any more direct investment in RVX at least until the share price improves dramatically. My guess is the only thing that will improve the share price will be a funded, significant trial where the funds have likely flowed through Zenith. Kind of a chicken and egg scenario. 

From an investor's perspective why invest directly into RVX when you can get a call on both companies by investing in Zenith. From the RVX perspective why try and obtain very dilutive equity investment when you can get non dilutive loans from Zenith.  Considering that Zenith is issuing Promissory notes with $1 (roughly) warrants, if an existing investor has proportionate holdings in each company then funds flowing through Zenith is probably the way to go currently. That is of course assuming both companies survive, no mean feat considering, IMO, the extra risks associated with CEO/governence. Especially in the case of RVX, where it is hard to fathom a business so completely botched in the face of so much opportunity. Faster and cheaper?

Share
New Message
Please login to post a reply